HalozymeHALO
HALO
About: Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Employees: 373
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
122% more first-time investments, than exits
New positions opened: 91 | Existing positions closed: 41
82% more call options, than puts
Call options by funds: $23.1M | Put options by funds: $12.7M
10% more funds holding
Funds holding: 456 [Q2] → 500 (+44) [Q3]
10% more capital invested
Capital invested by funds: $6.63B [Q2] → $7.26B (+$636M) [Q3]
7% more repeat investments, than reductions
Existing positions increased: 177 | Existing positions reduced: 166
0.8% more ownership
Funds ownership: 99.44% [Q2] → 100.24% (+0.8%) [Q3]
55% less funds holding in top 10
Funds holding in top 10: 11 [Q2] → 5 (-6) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$53
3%
downside
Avg. target
$63
15%
upside
High target
$73
33%
upside
4 analyst ratings
2 positive
50%
2 neutral
50%
0 negative
0%
Wells Fargo Mohit Bansal 31% 1-year accuracy 8 / 26 met price target | 4%upside $57 | Equal-Weight Maintained | 13 Jan 2025 |
Piper Sandler Joseph Catanzaro 27% 1-year accuracy 9 / 33 met price target | 3%downside $53 | Neutral Maintained | 10 Jan 2025 |
HC Wainwright & Co. Mitchell Kapoor 26% 1-year accuracy 43 / 164 met price target | 28%upside $70 | Buy Maintained | 10 Jan 2025 |
JMP Securities Jason Butler 31% 1-year accuracy 13 / 42 met price target | 33%upside $73 | Market Outperform Maintained | 1 Nov 2024 |
Financial journalist opinion
Based on 13 articles about HALO published over the past 30 days
Positive
Zacks Investment Research
6 days ago
5 Biotech Stocks Worth Adding to Your Portfolio in 2025
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry despite the uncertain macro environment. A strong portfolio and solid pipeline progress position INCY, BMRN, EXEL, HALO and BPMC well in this volatile sector.
Positive
Zacks Investment Research
1 week ago
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
Positive
Zacks Investment Research
1 week ago
HALO Raises 2025 Financial Guidance, Keeps 2024 View, Stock Up
Halozyme reiterates full-year 2024 financial guidance and raises its financial outlook for 2025. Shares rise.
Neutral
PRNewsWire
1 week ago
Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance
Reports Preliminary 2024 Unaudited Estimated Ranges Consistent with Previous Financial Guidance Raises 2025 Financial Guidance Ranges for Total Revenue to $1,150 - $1,225 million, Representing YoY Growth of 16% - 23%, Adjusted EBITDA of $755 - $805 million, Representing YoY Growth of 24% - 32%, and non-GAAP Diluted EPS of $4.95 - $5.35, Representing YoY Growth of 21% - 30%1,2 Announces New $250 million Accelerated Share Repurchase Conference Call Scheduled Today at 5:30am PT/8:30am ET SAN DIEGO , Jan. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full year 2024 financial guidance and raising full year 2025 and multi-year financial guidance. The Company also announced it has recently entered into a new $250 million accelerated share repurchase (ASR) program under its previously announced $750 million share repurchase program.
Positive
Zacks Investment Research
2 weeks ago
These 4 Stocks Boast Impressive Interest Coverage Ratios
LDOS, AMZN, HALO & BMRN's impressive interest coverage ratios highlight that these companies can withstand financial hardships.
Neutral
PRNewsWire
2 weeks ago
Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance
SAN DIEGO , Jan. 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday, January 8, 2025, at 5:30 a.m. PT / 8:30 a.m.
Positive
Seeking Alpha
2 weeks ago
Halozyme: 'Accidental' Business Model Has Exciting Upside Opportunities In 2025
Halozyme Therapeutics, Inc.'s subcu drug delivery business, driven by ENHANZE technology, shows strong revenue growth with significant collaborations, but faces potential challenges post-2030 due to expiring licensing agreements. The failed $2.1bn Evotec acquisition, while initially promising, may have been a blessing in disguise for HALO given Evotec's uncertain and loss-making business model. Recent approvals, including subcutaneous Opdivo (Qvantiq) and other products, e.g. Roche's Ocrevus, suggest a positive outlook for 2025, potentially boosting Halozyme's share price.
Positive
Seeking Alpha
2 weeks ago
Halozyme: Recent Approvals Alter My Appetite
Halozyme's attempt to acquire Evotec was a bold move to diversify revenue but was ultimately unsuccessful, impacting HALO's stock price. Despite a CRL for Rybrevant, Halozyme's technology saw success with FDA approval of Opdivo Qvantig, promising future royalty revenue. Halozyme's strong clinical track record and projected 20% CAGR in royalty revenue position it for significant growth through 2028.
Neutral
PRNewsWire
3 weeks ago
Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
SAN DIEGO , Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Takeda received regulatory approval for HYQVIA® [Immune Globulin Infusion 10% (Human) with Halozyme's Recombinant Human Hyaluronidase] by the Japanese Ministry of Health, Labour and Welfare (MHLW) for patients with agammaglobulinemia or hypogammaglobulinemia, disorders characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by primary immunodeficiency (PID) or secondary immunodeficiency (SID). HYQVIA® is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10% and one vial of Recombinant Human Hyaluronidase PH20 (rHuPH20), which is Halozyme's ENHANZE® drug delivery technology.
Neutral
PRNewsWire
3 weeks ago
Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy
SAN DIEGO , Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is co-formulated with Halozyme's ENHANZE® drug delivery technology, was granted regulatory approval by Japan's Ministry of Health, Labour and Welfare (MHLW) for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVDURA was approved for CIDP as a once weekly 30-to-90 second subcutaneous injection, which can be self-administered at home, and is the first and only neonatal Fc receptor (FcRn) blocker approved for the treatment of CIDP.
Charts implemented using Lightweight Charts™